Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 24, 2023

Pembrolizumab Plus Olaparib for Previously Treated, Biomarker-Unselected, Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
J. Clin. Oncol 2023 Jun 08;[EPub Ahead of Print], ES Antonarakis, SH Park, JC Goh, SJ Shin, JL Lee, N Mehra, R McDermott, N Sala-Gonzalez, PC Fong, R Greil, M Retz, JP Sade, P Yanez, YH Huang, SD Begbie, RA Gafanov, M De Santis, E Rosenbaum, MP Kolinsky, F Rey, KY Chiu, G Roubaud, G Kramer, M Sumitomo, F Massari, H Suzuki, P Qiu, J Zhang, J Kim, CH Poehlein, EY Yu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading